Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 46

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 46
---
 611,507 |
| NLS Common Shares issued to Kadimastem shareholders including convertible loans, restricted share units, or restricted share units, and options |     |       50,423,799 |     |         5,042,379 |
| Total NLS Common Shares and NLS Common Shares underlying outstanding Preferred Shares and PPCs outstanding at Closing                           |     |       56,538,856 |     |         5,653,885 |
| NLS Common Shares underlying warrants and options                                                                                               |     |        3,205,330 |     |           320,533 |
| Total NLS Common Shares outstanding as of Closing – Diluted                                                                                     |     |       59,744,186 |     |         5,974,418 |

____________ *Represents NLS’s outstanding shares as of October 3, 2025. *This gives effect to the reverse stock split of 1 -for-10as of October 30, 2025.

29

4.Reverse Stock Split NLS filed a notice of a reverse split with the commercial registry of the Canton of Zurich, Switzerland, on September 18, 2024. The reverse split became effective in Switzerland on September 18, 2024. The reverse stock split was at a ratio of 1 -for-40. In addition, on September 29, 2025, the NLS’s shareholders approved a further reverse stock split at a ratio of 1 -for-10, or the 2025 RSS. The accompanying unaudited pro forma condensed combined financial information does not give effect to the 2025 RSS, as certain procedural and regulatory steps required under Swiss corporate law remain outstanding before the split can be effectuated and become effective for accounting and reporting purposes. On October30, 2025, in connection with the Merger, the Registrant effected a 1 -for-10reverse stock split of the Company’s Common Shares, Preferred Shares and PPCs. The transactions contemplated by the Merger Agreement (including the Merger and the reverse stock split) were approved by the Company’s shareholders at the extraordinary general meeting of shareholders held on September29, 2025. 5.Estimated Purchase Price Consideration On November 4, 2024, NLS, Kadimastem and Merger Sub entered into the Merger Agreement, pursuant to which, Merger Sub will merge with and into Kadimastem, with Kadimastem surviving as a wholly